In:
Current Pharmaceutical Biotechnology, Bentham Science Publishers Ltd., Vol. 25, No. 1 ( 2024-01), p. 42-57
Abstract:
In this genomic era of addiction medicine, ideal treatment planning begins with genetic
screening to determine neurogenetic antecedents of the Reward Deficiency Syndrome (RDS) phenotype. Patients suffering from endotype addictions, both substance and behavioral, and other mental health/comorbid disorders that share the neurobiological commonality of dopamine dysfunction,
are ideal candidates for RDS solutions that facilitate dopamine homeostasis, addressing the cause, rather than symptoms. Our goal is to promote the interplay of molecular biology and
recovery as well as provide evidence linked to RDS and its scientific basis to primary care physicians and others. This was an observational case study with a retrospective chart review in which
an RDS treatment plan that utilized Genetic Addiction Risk Severity (GARS) analysis to evaluate neurogenetic challenges was used in order to develop appropriate short- and long-term pharmaceutical
and nutraceutical interventions. A Substance Use Disorder (SUD) treatment-resistant patient was successfully treated utilizing the GARS test and RDS science. The RDS Solution Focused
Brief Therapy (RDS-SFBT) and the RDS Severity of Symptoms Scale (SOS) may provide clinicians with a useful tool for establishing neurological balance and helping patients to achieve selfefficacy,
self-actualization, and prosperity.
Type of Medium:
Online Resource
ISSN:
1389-2010
DOI:
10.2174/1389201024666230427111117
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2024
SSG:
15,3
Permalink